CrushSCI.com
129.1Average days
124Median days
40Fastest days
225Longest days
1,7082025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

221 days

Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor

Authors
AK Kunzelmann; S Naehrig; C Shad; M Breuling; M Goetschke; K Habler; O Sommerburg; J Behr; LM Schatz; J Starp; M Vogeser; M Paal; U LiebchenShow moreShow less
Affiliations
Department of Anaesthesiology, LMU University Hospital, LMU Munich, 81377, Munich, Germany; Cystic Fibrosis Center for Adults, Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), 80336, Munich, Germany; Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Germany; Institute of Laboratory Medicine, LMU University Hospital, LMU Munich, 81377, Munich, Germany; Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics, University Hospital Heidelberg, Germany. Member of the German Center for Lung Research (DZL), GermanyShow moreShow less
Source PDF DOI Publisher page
43 days

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study

Authors
Emmanuelle Bardin; Hélène Salvator; Camille Roquencourt; Elodie Lamy; Nicolas Hunzinger; Isabelle Sermet-Gaudelus; Sandra De Miranda; Dominique Grenet; Philippe Devillier; Stanislas Grassin-DelyleShow moreShow less
Affiliations
Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades, Paris, France; Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation (2I), U1173, Département de Biotechnologie de la Santé, Unité Technologies pour la Santé et le Médicament, Montigny le Bretonneux, France; Hôpital Foch, Exhalomics®, Suresnes, France; Hôpital Necker Enfants Malades, Centre de Référence Maladies Rares, Paris, France; Université Paris-Saclay, UVSQ, UFR Simone Veil-Santé, VIM-Suresnes, UMR0892, Suresnes, France; Hôpital Foch, Service de pneumologie, CRCM - Centre de Transplantation Pulmonaire, Suresnes, FranceShow moreShow less
Source PDF DOI Publisher page
127 days

Is the gut a reservoir of non-tuberculous mycobacteria in people with cystic fibrosis?

Authors
Jennifer Hudson; Nicole Taylor; Michael J. Coffey; B.L.D. Uthpala Pushpakumara; Bernadette Prentice; Adam Jaffe; Simone Visser; Sheila Sivam; Andrew S. Day; Mark Oliver; Sarath Ranganathan; Hiran Selvadurai; Claire Wainwright; Chee Y. Ooi; Josie van DorstShow moreShow less
Affiliations
School of Clinical Medicine, Discipline of Paediatrics and Child Health, The University of New South Wales, Sydney, Australia; Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia; Department of Gastroenterology, Sydney Children’s Hospital, Randwick, Australia; Department of Respiratory Medicine, Sydney Children’s Hospital, Randwick, Australia; Sydney Medical School, University of Sydney, Camperdown, Australia; Department of Paediatrics and Child Health, University of Otago Christchurch, Christchurch, New Zealand; Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, Faculty of Medicine, The University of Melbourne, Melbourne, Australia; Respiratory Diseases, Murdoch Research Children's Institute, Royal Children's Hospital, Parkville, Victoria, Australia; Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia; Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Centre for Child Health Research, University of Queensland, South Brisbane, QLD, Australia; Department of Respiratory and Sleep Medicine, Queensland Children's Hospital Brisbane, South Brisbane, QLD, AustraliaShow moreShow less
Source PDF DOI Publisher page
108 days

Impact of ETI therapy on bone health, body composition and cardiopulmonary fitness in children with CF

Authors
A Holden; P Burns; A Devenny; L Thomson; R Langley; S Shepherd; A MasonShow moreShow less
Affiliations
University of Glasgow, Glasgow, UK; Department of Sleep and Respiratory Physiology, Royal Hospital for Children, Glasgow, UK; Department of Paediatric Respiratory Medicine, Royal Hospital for Children, Glasgow, UK; Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UKShow moreShow less
Source PDF DOI Publisher page
136 days

Economic evaluation of CFTR modulator therapies in cystic fibrosis: a cost-benefit and cost-effectiveness perspective from the REMEDIA European commission project

Authors
Ariel Beresniak; A Daruich; Matthieu Patrice Robert; L Niddam; A Juusti-Hawkes; D Bremond-GignacShow moreShow less
Affiliations
Data Mining International, Geneva, Switzerland; INSERM UMRS 1138, Team 17, Paris, France; OPHTARA Rare Diseases Center, University Hospital Necker Enfants malades, AP-HP, Paris, France; Wellspring, Budapest, HungaryShow moreShow less
Source PDF DOI Publisher page
161 days

Lung mucus burden and treatment response assessed by MRI in the post-modulator era

Authors
Alexander M Matheson; Evan Prather; Matthew M Willmering; Jaime Mata; Giles Santyr; Felix A Ratjen; Elizabeth L Kramer; Zackary I Cleveland; Jason C WoodsShow moreShow less
Affiliations
Center for Pulmonary Imaging Research, Cincinnati Children's Hospital, Cincinnati, OH, United States; Pulmonary Medicine, Cincinnati Children's Hospital, Cincinnati, OH, United States; Department of Pediatrics, The University of Cincinnati, Cincinnati, OH, United States; College of Medicine, The University of Cincinnati, Cincinnati, OH, United States; University of Virginia, Virginia, VA, United States; Department of Radiology, The Hospital for Sick Children, Toronto, ON, Canada; Translational Medicine Program, The Hospital for Sick Children, Toronto, ON, CanadaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Journal of Cystic Fibrosis take to review a manuscript?

As of 2026-11-19, CrushSCI has 15 complete review records for Journal of Cystic Fibrosis. The fastest paper went from submission to acceptance in 40 days (Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy, received 2026-02-01, accepted 2026-03-13); the slowest took 225 days. The average is 129.1 days and the median is 124 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.